Principal-versus-Agent Considerations in Revenue Recognition Under ASC 606 and Compliance Risk
The Accounting Review · 01.05.2026 · 101 (3) · 467-492
DOI: 10.2308/tar-2022-0298 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Accounting Review, online erschienen am 16.04.2026. Verfasst von Kai Du und 3 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben.
Abstract (Originalsprache)
Using a dataset constructed through textual analysis and manual data collection, we show that, prior to ASC 606, firms with principal-versus-agent (PA) exposure face heightened GAAP compliance risk, reflected in a greater likelihood of receiving revenue-related SEC comment letters and higher audit fees. Following the adoption of ASC 606, these differences decline, consistent with the standard’s stated goal of simplifying PA assessments and reducing implementation challenges. Overall, our findings provide the first large-sample evidence on PA considerations and show that ASC 606 mitigates compliance risk, although further analyses suggest additional disclosure may be needed to mitigate information challenges associated with PA assessments. Data Availability: Data are available from the public sources cited in the text. JEL Classifications: L86; M41; M42; M48.
Zitieren
APA
Du, K., Louis, H., Schmidt, B. A., & Wang, S. (2026). Principal-versus-Agent Considerations in Revenue Recognition Under ASC 606 and Compliance Risk. The Accounting Review, 101(3), 467-492. https://doi.org/10.2308/tar-2022-0298
Vancouver
Du K, Louis H, Schmidt BA, Wang S. Principal-versus-Agent Considerations in Revenue Recognition Under ASC 606 and Compliance Risk. The Accounting Review. 2026;101(3):467-492. doi:10.2308/tar-2022-0298
BibTeX
@article{Du2026,
author = {Du, Kai and Louis, Henock and Schmidt, Brent A. and Wang, Shuyang},
title = {Principal-versus-Agent Considerations in Revenue Recognition Under ASC 606 and Compliance Risk},
journal = {The Accounting Review},
year = {2026},
volume = {101},
number = {3},
pages = {467--492},
doi = {10.2308/tar-2022-0298}
}
EUVIMED